ATP therapy for tachyarrhythmias in VF zone

• US 20060025822A1
• Filed: 08/02/2004
• Published: 02/02/2006
• Est. Priority Date: 08/02/2004
• Status: Active Grant

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Zhang, Yunlong
• Granted Patent: US 7,477,942 B2
• Time in Patent Office: Days
• US Class Current: 607/4
• CPC Class Codes: A61N 1/3622 comprising two or more electrodes co-operating with different heart regions
• CPC Class Codes: A61N 1/39622 Pacing therapy

Abstract

A method and apparatus for delivering therapy to treat ventricular tachyarrhythmias is described. A ventricular tachyarrhythmia can be classified into tachycardia or fibrillation zones using a rate criterion so that the tachyarrhythmia can be treated with either anti-tachycardia pacing or shock therapy, respectively. Rate stability and morphology criteria are employed to determine if a tachyarrhythmia in the fibrillation zone is actually monomorphic ventricular tachycardia which can be treated with ATP.

Claims

1. A method for delivering anti-tachyarrhythmia therapy, comprising:

generating an electrogram signal representing electrical activity in a ventricle;

detecting ventricular senses and measuring a time interval between ventricular senses (RR intervals) to determine a current ventricular rate;

detecting a ventricular tachyarrhythmia when the ventricular rate exceeds a specified tachycardia detection rate (TDR);

upon detection of a ventricular tachyarrhythmia, delivering anti-tachycardia pacing (ATP) therapy if the ventricular rate is below a fibrillation detection rate (FDR);

upon detection of a ventricular tachyarrhythmia and if the ventricular rate is above the FDR, determining if a specified number of beats during the tachyarrhythmia meet a specified rate stability criterion and a specified monomorphic morphology criterion;

if the specified rate stability and monomorphic morphology criteria are met, delivering anti-tachycardia pacing (ATP) therapy; and

,

if the specified rate stability and monomorphic morphology criteria are not met, delivering shock therapy.

2. The method of claim 1 further comprising delivering shock therapy upon detection of a ventricular tachyarrhythmia, without determining if the specified rate stability and monomorphic morphology criteria are met, if the ventricular rate is above the FDR and also above a specified monomorphic ventricular tachycardia upper limit (MVTUL).

3. The method of claim 1 wherein the rate stability criterion requires that the intervals between a specified number of successive ventricular senses during the tachyarrhythmia are relatively regular and exhibit no more than a specified amount of variation.

4. The method of claim 3 further comprising determining whether the rate stability criterion is met by computing a variance or similar statistic of successive RR intervals and comparing the statistic with a specified rate stability limit value.

5. The method of claim 1 wherein the monomorphic morphology criterion requires that the QRS complexes of the ventricular electrogram during the tachyarrhythmia are relatively constant from beat to beat.

6. The method of claim 5 further comprising analyzing the morphology of the tachyarrhythmia by determining the degree of similarity between the electrogram waveforms of a specified number of successive ventricular beats.

7. The method of claim 6 further comprising determining the degree of similarity between the electrogram waveforms by performing cross-correlations between the electrogram waveforms of successive ventricular beats.

8. The method of claim 7 wherein the cross-correlation operations are applied to amplitudes of the electrograms.

9. The method of claim 1 further comprising delivering shock therapy if the ATP therapy is unsuccessful in terminating the tachyarrhythmia.

10. The method of claim 9 further comprising repeating ATP therapy for a specified time period if the tachyarrhythmia is not terminated before delivering shock therapy.

11. A cardiac device, comprising:

a sensing channel for generating an electrogram signal representing electrical activity in a ventricle;

a pacing channel for delivering anti-tachycardia pacing (ATP) to a ventricle;

a shocking channel for delivering shock therapy to a ventricle;

a controller, wherein the controller is programmed to;

detect ventricular senses and measure a time interval between ventricular senses (RR intervals) to determine a current ventricular rate;

detect a ventricular tachyarrhythmia when the ventricular rate exceeds a specified tachycardia detection rate (TDR);

upon detection of a ventricular tachyarrhythmia, deliver anti-tachycardia pacing (ATP) therapy if the ventricular rate is below a fibrillation detection rate (FDR);

upon detection of a ventricular tachyarrhythmia and if the ventricular rate is above the FDR, determine if a specified number of beats during the tachyarrhythmia meet a specified rate stability criterion and a specified monomorphic morphology criterion;

if the specified rate stability and monomorphic morphology criteria are met, deliver anti-tachycardia pacing (ATP) therapy; and

,

if the specified rate stability and monomorphic morphology criteria are not met, deliver shock therapy.

12. The device of claim 11 wherein the controller is programmed to deliver shock therapy upon detection of a ventricular tachyarrhythmia, without determining if the specified rate stability and monomorphic morphology criteria are met, if the ventricular rate is above the FDR and also above a specified monomorphic ventricular tachycardia upper limit (MVTUL).

13. The device of claim 11 wherein the rate stability criterion requires that the intervals between a specified number of successive ventricular senses during the tachyarrhythmia are relatively regular and exhibit no more than a specified amount of variation.

14. The device of claim 13 wherein the controller is programmed to determine whether the rate stability criterion is met by computing a variance or similar statistic of successive RR intervals and compare the statistic with a specified rate stability limit value.

15. The device of claim 11 wherein the monomorphic morphology criterion requires that the QRS complexes of the ventricular electrogram during the tachyarrhythmia are relatively constant from beat to beat.

16. The device of claim 15 wherein the controller is programmed to analyze the morphology of the tachyarrhythmia by determining the degree of similarity between the electrogram waveforms of a specified number of successive ventricular beats.

17. The device of claim 16 wherein the controller is programmed to determine the degree of similarity between the electrogram waveforms by performing cross-correlations between the electrogram waveforms of successive ventricular beats.

18. The device of claim 17 wherein the cross-correlation operations are applied to amplitudes of the electrograms.

19. The device of claim 11 wherein the controller is programmed to deliver shock therapy if the ATP therapy is unsuccessful in terminating the tachyarrhythmia.

20. The device of claim 19 wherein the controller is programmed to repeat ATP therapy for a specified time period if the tachyarrhythmia is not terminated before delivering shock therapy.